Comparison of the efficacy and safety between flumatinib and imatinib in newly diagnosed chronic myeloid leukemia
10.3760/cma.j.issn.1009-9921.2016.09.003
- VernacularTitle:氟马替尼与伊马替尼治疗初诊慢性粒细胞白血病的有效性和安全性比较
- Author:
Jia LIU
;
Xiaobao XIE
;
Weiying GU
;
Xiaomei ZHANG
;
Aining SUN
;
Xiaoyan ZHANG
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,chronic;
Flumatinib;
Imatinib;
Main molecular remission;
Safety
- From:
Journal of Leukemia & Lymphoma
2016;25(9):526-530
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety between flumatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML). Methods A multi-center, randomized and parallel comparison clinical trial was conducted in 24 newly diagnosed patients with Philadelphia chromosome-positive CML-chronic phase (Ph+ CML-CP) who were treated by flumatinib 400 mg/d, 600 mg/d or imatinib for 6 cycles (24 weeks). The hematology was evaluated at pre-medication and the 2nd, 4th, 6th, 8th, 10th, 12th, 16th, 20th, 24th week of post-medication. The morphology, cytogenetics and molecular biology were evaluated at pre-medication and 12th, 24th week of post-medication. Results In terms of efficacy, the main molecular remission (MMR) rate of flumatinib 600 mg/d group was higher than that of imatinib group after 24 weeks [44.44 % (4/9) vs. 14.29 % (1/7), P=0.017]. The rate of bcr-ablIS≤10 % in flumatinib 600 mg/d group was significantly higher than that in imatinib group (P=0.002). PK/PD analysis also hinted that patients treated by flumatinib 600 mg/d was more likely to get molecular reaction in the early stage compared with those treated by flumatinib 400 mg/d. In terms of safety, there was no significant difference in grade Ⅲ-Ⅳ of adverse events among flumatinib 400 mg/d group, flumatinib 600 mg/d group and imatinib group (P >0.05). The common adverse events in flumatinib group included skin toxicity, gastrointestinal reactions and diarrhea.There was no heart and cardiovascular toxicity in flumatinib group, and incidence of edema in flumatinib group was lower than that in imatinib group. Conclusions Flumatinib is a safe and effective drug for newly diagnosed patients with Ph+ CML-CP, and 600 mg/d is the appropriate clinical starting dose. Flumatinib and imatinib have similar safety in clinic.
